Abstract:Rationale: Cancer stem cells (CSCs) have been implicated as the seeds of therapeutic resistance and metastasis, due to their unique abilities of self-renew, wide differentiation potentials and resistance to most conventional therapies. It is a proactive strategy for cancer therapy to eradicate CSCs. Methods: Tumor tissue-derived breast CSCs (BCSC), including XM322 and XM607, were isolated by fluorescence-activated cell sorting (FACS); while cell line-derived BCSC, including MDA-MB-231.SC and MCF-7.SC, were purified by magnetic-activated cell sorting (MACS). Analyses of microRNA and mRNA expression array profiles were performed in multiple breast cell lines. The mentioned nanoparticles were constructed following the standard molecular cloning protocol. Tissue microarray analysis has been used to study 217 cases of clinical breast cancer specimens. Results: Here, we have successfully established four long-term maintenance BCSC that retain their tumor-initiating biological properties. Our analyses of microarray and qRT-PCR explored that miR-34a is the most pronounced microRNA for investigation of BCSC. We establish hTERT promoter-driven VISA delivery of miR-34a (TV-miR-34a) plasmid that can induce high throughput of miR-34a expression in BCSC. TV-miR-34a significantly inhibited the tumor-initiating properties of long-term-cultured BCSC in vitro and reduced the proliferation of BCSC in vivo by an efficient and safe way. TV-miR-34a synergizes with docetaxel, a standard therapy for invasive breast cancer, to act as a BCSC inhibitor. Further mechanistic investigation indicates that TV-miR-34a directly prevents C22ORF28 accumulation, which abrogates clonogenicity and tumor growth and correlates with low miR-34 and high C22ORF28 levels in breast cancer patients. Conclusion: Taken together, we generated four long-term maintenance BCSC derived from either clinical specimens or cell lines, which would be greatly beneficial to the research progress in breast cancer patients. We further developed the non-viral TV-miR-34a plasmid, which has a great potential to be applied as a clinical application for breast cancer therapy.

A Recombinant Protein TmSm(T34A) Can Inhibit Proliferation and Proapoptosis to Breast Cancer Stem Cells(bcscs) by Down-Regulating the Expression of Cyclin D1.

Discovering and Characterizing of Survivin Dominant Negative Mutants With Stronger Pro-apoptotic Activity on Cancer Cells and CSCs

Nanoparticle Delivery of Mir-34A Eradicates Long-term-cultured Breast Cancer Stem Cells Via Targeting C22ORF28 Directly

The Influence of Mir-34A Expression on Stemness and Cytotoxic Susceptibility of Breast Cancer Stem Cells

Resveratrol Inhibits Breast Cancer Stem-Like Cells and Induces Autophagy Via Suppressing Wnt/β-catenin Signaling Pathway.

Mir-376C-3p Modulates the Properties of Breast Cancer Stem Cells by Targeting RAB2A.

Effect on Apoptosis and Cell Cycle of Recombinant Double Negative Dominant Mutation Survivin (T34/117A) in Breast Cancer Cell B-Cap-37

Effects of recombinant protein TATm-Survivin(T34/117A) on cell cycle and apoptosis of B-Cap-37 cell

A novel derivative of artemisinin inhibits cell proliferation and metastasis via down-regulation of cathepsin K in breast cancer.

Protein C Receptor is a Therapeutic Stem Cell Target in a Distinct Group of Breast Cancers

The anti-tumor immune response of specific cytotoxic T lymphocytes induced by breast cancer stem cells RNA-DCs vaccine

Role, Molecular Mechanism and the Potential Target of Breast Cancer Stem Cells in Breast Cancer Development

Reduced Tumorigenicity and Drug Resistance Through the Downregulation of Octamer-Binding Protein 4 and Nanog Transcriptional Factor Expression in Human Breast Stem Cells

Compound Nanoemulsion Combined with Differentiation/Cytotoxicity Drugs for Modulating Breast Cancer Stemness.

Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness.

Modulation of Drug-Resistant Membrane and Apoptosis Proteins of Breast Cancer Stem Cells by Targeting Berberine Liposomes

Biomimetic Nano‐Cancer Stem Cell Scavenger for Inhibition of Breast Cancer Recurrence and Metastasis after FLASH‐Radiotherapy

Elevated CRB3 Expression Suppresses Breast Cancer Stemness by Inhibiting Β‐catenin Signalling to Restore Tamoxifen Sensitivity

Downregulation of CXCR7 Inhibits Proliferative Capacity and Stem Cell-Like Properties in Breast Cancer Stem Cells

Biomimetic "nano-spears" for CAFs-targeting: splintered three "shields" with enhanced cisplatin anti-TNBC efficiency

Genetic Protein TmSm(T34A) Enhances Sensitivity of Chemotherapy to Breast Cancer Cell Lines As a Synergistic Drug to Doxorubicin